|  Help  |  About  |  Contact Us

Search our database by keyword

Examples

  • Search this entire website. Enter identifiers, names or keywords for genes, diseases, strains, ontology terms, etc. (e.g. Pax6, Parkinson, ataxia)
  • Use OR to search for either of two terms (e.g. OR mus) or quotation marks to search for phrases (e.g. "dna binding").
  • Boolean search syntax is supported: e.g. Balb* for partial matches or mus AND NOT embryo to exclude a term

Search results 1 to 100 out of 1742 for Fasl

<< First    < Previous  |  Next >    Last >>
0.039s

Categories

Hits by Pathway

Hits by Strain

Hits by Category

Type Details Score
Protein Domain
Type: Family
Description: Like all apoptotic cell death, T cell receptor (TCR)-mediated death can bedivided into two phases: an inductive phase and an effector phase. The effector phase includes a sequence of steps that are common to apoptosis inmany cell types, which, if not interrupted, will lead to cell death. Theinduction phase, which often requires the expression of new genes, consistsof a set of signals that activate the effector phase. Outside the thymus,most, if not all, of the TCR-mediated apoptosis ofmature T cells (sometimesreferred to as activation-induced cell death (AICD)) is induced through thesurface antigen Fas pathway: activation through the TCR induces expressionof the Fas (CD95) ligand (FasL); the expression of FasL on either aneighbouring cell, or on the Fas-bearing cell, induces trimerisation of Fas,which then initiates a signal-transduction cascade, leading to apoptosis of the Fas-bearing cell. This commitment stage requires the activation of keydeath-inducing enzymes, termed caspases, which act by cleaving proteins thatare essential for cell survival and proliferation[, ]. However whathappens to FasL itself remains unknown. It is possible that it is cleavedfrom the effector cells and internalised into the target cells; it may bedownregulated in the effector cells; or it may be phagocytosed by the targetcells.Fas is also known to be essential in the death of hyperactivated peripheralCD4 cells: in the absence of Fas, mature peripheral T cells do not die, butthe activated cells continue to proliferate, producing cytokines that leadto grossly enlarged lymph nodes and spleen. Defects in the Fas-FasL systemare associated with various disease syndromes. Mice with non-functional Fasor FasL display characteristics of lymphoproliferative disorder, such as lymphadenopathy, splenomegaly, and elevated secretion of IgM and IgG. Thesemice also secrete anti-DNA autoantibodies and rheumatoid factor [].FasL (also known as tumor necrosis factor ligand superfamily member 6) is a 40kDa type II membrane protein belonging to the tumour necrosisfactor (TNF) family. Its binding to the cognate Fas receptor triggers the apoptosis that plays a pivotal role in the maintenance of immune system homeostasis. It is expressed on activated lymphocytes, NK cells,platelets, certain immune-privileged cells and some tumour cells[, ]. The cell death-inducing property of FasL has been associated with its extracellular domain, which can be cleaved off by metalloprotease activity to produce soluble FasL [].Human and mouse FasL induce apoptosis in cells expressing either mouse orhuman Fas with the same specificity. Although the amino acid sequence ofFasL is highly conserved between human and mouse, the similarity betweenhuman and murine Fas is much less pronounced. Greater conservation of theligand than the receptor is also observed in other members of the TNF family.By comparison with other TNF family members, FasL has a long N-terminal intracellular region rich in proline residues, which is known to bind to the SH3 domain. SH3 domains play important roles in mediating specificprotein-protein interactions, specifically in the cytoskeleton.
Protein Coding Gene
Type: protein_coding_gene
Organism: Mus musculus
Protein
Organism: Mus musculus
Length: 131  
Fragment?: false
Protein
Organism: Mus musculus
Length: 279  
Fragment?: false
Protein
Organism: Mus musculus
Length: 279  
Fragment?: false
Protein
Organism: Mus musculus
Length: 279  
Fragment?: false
Publication
First Author: Takahashi T
Year: 1994
Journal: Int Immunol
Title: Human Fas ligand: gene structure, chromosomal location and species specificity.
Volume: 6
Issue: 10
Pages: 1567-74
Publication
First Author: Wenzel J
Year: 2001
Journal: FEBS Lett
Title: Multiple interactions of the cytosolic polyproline region of the CD95 ligand: hints for the reverse signal transduction capacity of a death factor.
Volume: 509
Issue: 2
Pages: 255-62
Protein
Organism: Mus musculus
Length: 279  
Fragment?: false
Publication
First Author: Kirkin V
Year: 2007
Journal: Cell Death Differ
Title: The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells.
Volume: 14
Issue: 9
Pages: 1678-87
Publication
First Author: Yankee TM
Year: 2001
Journal: Proc Natl Acad Sci U S A
Title: CD95/Fas induces cleavage of the GrpL/Gads adaptor and desensitization of antigen receptor signaling.
Volume: 98
Issue: 12
Pages: 6789-93
Publication
First Author: Lynch DH
Year: 1995
Journal: Immunol Today
Title: Fas and FasL in the homeostatic regulation of immune responses.
Volume: 16
Issue: 12
Pages: 569-74
Publication
First Author: Tan S
Year: 2019
Journal: Cell Death Dis
Title: IL-6-driven FasL promotes NF-κBp65/PUMA-mediated apoptosis in portal hypertensive gastropathy.
Volume: 10
Issue: 10
Pages: 748
Publication
First Author: Embree-Ku M
Year: 2002
Journal: Toxicol Pathol
Title: FasL deficiency enhances the development of tumors in p53+/- mice.
Volume: 30
Issue: 6
Pages: 705-13
Publication
First Author: He JS
Year: 2007
Journal: J Immunol
Title: CTLs contain and use intracellular stores of FasL distinct from cytolytic granules.
Volume: 179
Issue: 4
Pages: 2339-48
Publication
First Author: Semkova I
Year: 2006
Journal: FASEB J
Title: Overexpression of FasL in retinal pigment epithelial cells reduces choroidal neovascularization.
Volume: 20
Issue: 10
Pages: 1689-91
Publication
First Author: Lau HT
Year: 1996
Journal: Science
Title: Prevention of islet allograft rejection with engineered myoblasts expressing FasL in mice.
Volume: 273
Issue: 5271
Pages: 109-12
Publication
First Author: Wang CC
Year: 2006
Journal: Biochem Biophys Res Commun
Title: Mouse lymphomas caused by an intron-splicing donor site deletion of the FasL gene.
Volume: 349
Issue: 1
Pages: 50-8
Publication
First Author: Wang X
Year: 2006
Journal: Cell Death Differ
Title: Activation of extracellular signal-regulated protein kinase 5 downregulates FasL upon osmotic stress.
Volume: 13
Issue: 12
Pages: 2099-108
Publication
First Author: Schulte M
Year: 2007
Journal: Cell Death Differ
Title: ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death.
Volume: 14
Issue: 5
Pages: 1040-9
Publication
First Author: Sato A
Year: 2014
Journal: PLoS One
Title: Involvement of the TNF and FasL produced by CD11b Kupffer cells/macrophages in CCl4-induced acute hepatic injury.
Volume: 9
Issue: 3
Pages: e92515
Publication
First Author: Fujikura D
Year: 2013
Journal: PLoS One
Title: Type-I interferon is critical for FasL expression on lung cells to determine the severity of influenza.
Volume: 8
Issue: 2
Pages: e55321
Publication
First Author: Cohen PY
Year: 2009
Journal: Am J Respir Cell Mol Biol
Title: Thy1 up-regulates FasL expression in lung myofibroblasts via Src family kinases.
Volume: 40
Issue: 2
Pages: 231-8
Publication
First Author: O'Reilly LA
Year: 2015
Journal: Cell Death Differ
Title: Loss of c-REL but not NF-κB2 prevents autoimmune disease driven by FasL mutation.
Volume: 22
Issue: 5
Pages: 767-78
Publication
First Author: Embree-Ku M
Year: 2002
Journal: Exp Biol Med (Maywood)
Title: Absence of p53 and FasL has sexually dimorphic effects on both development and reproduction.
Volume: 227
Issue: 7
Pages: 545-53
Publication
First Author: Yao PL
Year: 2007
Journal: J Biol Chem
Title: Transcriptional regulation of FasL expression and participation of sTNF-alpha in response to sertoli cell injury.
Volume: 282
Issue: 8
Pages: 5420-31
Publication
First Author: Shanker A
Year: 2015
Journal: Cancer Res
Title: Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.
Volume: 75
Issue: 24
Pages: 5260-72
Publication
First Author: Legge KL
Year: 2005
Journal: Immunity
Title: Lymph node dendritic cells control CD8+ T cell responses through regulated FasL expression.
Volume: 23
Issue: 6
Pages: 649-59
Publication
First Author: Gorbachev AV
Year: 2010
Journal: Eur J Immunol
Title: CD4+CD25+ regulatory T cells utilize FasL as a mechanism to restrict DC priming functions in cutaneous immune responses.
Volume: 40
Issue: 7
Pages: 2006-15
Publication
First Author: Mohamood AS
Year: 2007
Journal: Am J Pathol
Title: Protection from autoimmune diabetes and T-cell lymphoproliferation induced by FasL mutation are differentially regulated and can be uncoupled pharmacologically.
Volume: 171
Issue: 1
Pages: 97-106
Publication
First Author: Lin YC
Year: 2010
Journal: Toxicol Sci
Title: FasL gene-deficient mice display a limited disruption in spermatogenesis and inhibition of mono-(2-ethylhexyl) phthalate-induced germ cell apoptosis.
Volume: 114
Issue: 2
Pages: 335-45
Publication
First Author: Hornick EE
Year: 2019
Journal: J Clin Invest
Title: Dendritic cell NLRC4 regulates influenza A virus-specific CD4 T cell responses through FasL expression.
Volume: 129
Issue: 7
Pages: 2888-2897
Publication
First Author: Chung CS
Year: 2001
Journal: Am J Physiol Gastrointest Liver Physiol
Title: Increased apoptosis in lamina propria B cells during polymicrobial sepsis is FasL but not endotoxin mediated.
Volume: 280
Issue: 5
Pages: G812-8
Publication
First Author: Villa-Morales M
Year: 2010
Journal: Carcinogenesis
Title: Modulation of the Fas-apoptosis-signalling pathway by functional polymorphisms at Fas, FasL and Fadd and their implication in T-cell lymphoblastic lymphoma susceptibility.
Volume: 31
Issue: 12
Pages: 2165-71
Publication
First Author: Villa-Morales M
Year: 2007
Journal: Cancer Res
Title: A role for the Fas/FasL system in modulating genetic susceptibility to T-cell lymphoblastic lymphomas.
Volume: 67
Issue: 11
Pages: 5107-16
GO Term
GO Term
GO Term
GO Term
Component
Name: ADAM10-processed FasL form
Component
Name: FasL intracellular domain
Publication
First Author: Nagata S
Year: 1995
Journal: Science
Title: The Fas death factor.
Volume: 267
Issue: 5203
Pages: 1449-56
UniProt Feature
Begin: 1
Description: FasL intracellular domain
Type: chain
End: 80
UniProt Feature
Begin: 1
Description: ADAM10-processed FasL form
Type: chain
End: 127
Publication
First Author: Zhu B
Year: 2000
Journal: Eur J Immunol
Title: Double mutant MRL-lpr/lpr-gld/gld cells fail to trigger lpr-graft-versus-host disease in syngeneic wild-type recipient mice, but can induce wild-type B cells to make autoantibody.
Volume: 30
Issue: 6
Pages: 1778-84
Publication
First Author: Takahashi T
Year: 1994
Journal: Cell
Title: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand.
Volume: 76
Issue: 6
Pages: 969-76
Publication
First Author: Hahne M
Year: 1995
Journal: Int Immunol
Title: Characterization of the non-functional Fas ligand of gld mice.
Volume: 7
Issue: 9
Pages: 1381-6
Publication
First Author: Hägglöf T
Year: 2016
Journal: Nat Immunol
Title: Neutrophils license iNKT cells to regulate self-reactive mouse B cell responses.
Volume: 17
Issue: 12
Pages: 1407-1414
Publication
First Author: Figgett WA
Year: 2013
Journal: Immunity
Title: The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death.
Volume: 39
Issue: 3
Pages: 573-83
Publication
First Author: Tsutsui H
Year: 1999
Journal: Immunity
Title: Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice.
Volume: 11
Issue: 3
Pages: 359-67
Publication
First Author: Mabrouk I
Year: 2008
Journal: Immunity
Title: Prevention of autoimmunity and control of recall response to exogenous antigen by Fas death receptor ligand expression on T cells.
Volume: 29
Issue: 6
Pages: 922-33
Publication
First Author: Kong S
Year: 2016
Journal: Proc Natl Acad Sci U S A
Title: Endoplasmic reticulum-resident E3 ubiquitin ligase Hrd1 controls B-cell immunity through degradation of the death receptor CD95/Fas.
Volume: 113
Issue: 37
Pages: 10394-9
Publication
First Author: Langlois RA
Year: 2010
Journal: J Immunol
Title: Plasmacytoid dendritic cells enhance mortality during lethal influenza infections by eliminating virus-specific CD8 T cells.
Volume: 184
Issue: 8
Pages: 4440-6
Publication
First Author: Gregory MS
Year: 2011
Journal: PLoS One
Title: Opposing roles for membrane bound and soluble Fas ligand in glaucoma-associated retinal ganglion cell death.
Volume: 6
Issue: 3
Pages: e17659
Publication
First Author: Karray S
Year: 2004
Journal: J Immunol
Title: Complete loss of Fas ligand gene causes massive lymphoproliferation and early death, indicating a residual activity of gld allele.
Volume: 172
Issue: 4
Pages: 2118-25
Publication
First Author: Huang X
Year: 2011
Journal: J Dent Res
Title: Tgf-beta-mediated FasL-Fas-Caspase pathway is crucial during palatogenesis.
Volume: 90
Issue: 8
Pages: 981-7
Publication
First Author: Potter CS
Year: 2017
Journal: Exp Dermatol
Title: Loss of FAS/FASL signalling does not reduce apoptosis in Sharpin null mice.
Volume: 26
Issue: 9
Pages: 820-822
Publication
First Author: Dittel BN
Year: 1999
Journal: J Immunol
Title: Evidence for Fas-dependent and Fas-independent mechanisms in the pathogenesis of experimental autoimmune encephalomyelitis.
Volume: 162
Issue: 11
Pages: 6392-400
Publication
First Author: Sata M
Year: 2000
Journal: J Mol Cell Cardiol
Title: Fas ligand-deficient mice display enhanced leukocyte infiltration and intima hyperplasia in flow-restricted vessels.
Volume: 32
Issue: 8
Pages: 1395-400
Publication
First Author: Kaplan HJ
Year: 1999
Journal: Nat Med
Title: Fas ligand (CD95 ligand) controls angiogenesis beneath the retina.
Volume: 5
Issue: 3
Pages: 292-7
Publication
First Author: Weih F
Year: 1996
Journal: Proc Natl Acad Sci U S A
Title: Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway.
Volume: 93
Issue: 11
Pages: 5533-8
Publication
First Author: Barreiro R
Year: 2004
Journal: J Immunol
Title: Termination of antigen-specific immunity by CD95 ligand (Fas ligand) and IL-10.
Volume: 173
Issue: 3
Pages: 1519-25
Publication
First Author: Crawford HC
Year: 2002
Journal: J Clin Invest
Title: Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.
Volume: 109
Issue: 11
Pages: 1437-44
Publication
First Author: Hoek RM
Year: 1997
Journal: J Immunol Methods
Title: Allele-specific PCR analysis for detection of the gld Fas-ligand point mutation.
Volume: 210
Issue: 1
Pages: 109-12
Publication
First Author: Waldner H
Year: 1997
Journal: J Immunol
Title: Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.
Volume: 159
Issue: 7
Pages: 3100-3
Publication
First Author: Hahne M
Year: 1996
Journal: Eur J Immunol
Title: Activated B cells express functional Fas ligand.
Volume: 26
Issue: 3
Pages: 721-4
Publication
First Author: Petri S
Year: 2006
Journal: J Neurol Sci
Title: Loss of Fas ligand-function improves survival in G93A-transgenic ALS mice.
Volume: 251
Issue: 1-2
Pages: 44-9
Publication
First Author: Couillard M
Year: 2002
Journal: Cancer Res
Title: c-myc-induced apoptosis in polycystic kidney disease is independent of FasL/Fas interaction.
Volume: 62
Issue: 8
Pages: 2210-4
Publication
First Author: Jonsson H
Year: 2005
Journal: Nat Med
Title: Inflammatory arthritis requires Foxo3a to prevent Fas ligand-induced neutrophil apoptosis.
Volume: 11
Issue: 6
Pages: 666-71
Publication
First Author: Hill RA
Year: 2007
Journal: Mol Cell Neurosci
Title: Fas/FasL-mediated apoptosis in the arcuate nucleus and medial preoptic area of male ArKO mice is ameliorated by selective estrogen receptor alpha and estrogen receptor beta agonist treatment, respectively.
Volume: 36
Issue: 2
Pages: 146-57
Publication
First Author: Arai H
Year: 1997
Journal: Proc Natl Acad Sci U S A
Title: Gene transfer of Fas ligand induces tumor regression in vivo.
Volume: 94
Issue: 25
Pages: 13862-7
Publication
First Author: Matsui K
Year: 1998
Journal: J Immunol
Title: Identification of two NF-kappa B sites in mouse CD95 ligand (Fas ligand) promoter: functional analysis in T cell hybridoma.
Volume: 161
Issue: 7
Pages: 3469-73
Publication
First Author: Bonfoco E
Year: 1998
Journal: Immunity
Title: Inducible nonlymphoid expression of Fas ligand is responsible for superantigen-induced peripheral deletion of T cells.
Volume: 9
Issue: 5
Pages: 711-20
Publication
First Author: Xiao S
Year: 2004
Journal: J Immunol
Title: Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail: evidence for translational regulation and against Fas ligand retention in secretory lysosomes.
Volume: 173
Issue: 8
Pages: 5095-102
Publication
First Author: Sun M
Year: 2006
Journal: J Immunol
Title: The cytoplasmic domain of Fas ligand costimulates TCR signals.
Volume: 177
Issue: 3
Pages: 1481-91
Publication
First Author: Hassin D
Year: 2011
Journal: Immunology
Title: Cytotoxic T lymphocyte perforin and Fas ligand working in concert even when Fas ligand lytic action is still not detectable.
Volume: 133
Issue: 2
Pages: 190-6
Publication
First Author: Kidoya H
Year: 2005
Journal: J Immunol
Title: Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production.
Volume: 175
Issue: 12
Pages: 8024-31
Publication
First Author: Lynch DH
Year: 1994
Journal: Immunity
Title: The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster.
Volume: 1
Issue: 2
Pages: 131-6
Publication
First Author: Ayroldi E
Year: 1999
Journal: Blood
Title: Cloning and expression of a short Fas ligand: A new alternatively spliced product of the mouse Fas ligand gene.
Volume: 94
Issue: 10
Pages: 3456-67
Publication
First Author: O' Reilly LA
Year: 2009
Journal: Nature
Title: Membrane-bound Fas ligand only is essential for Fas-induced apoptosis.
Volume: 461
Issue: 7264
Pages: 659-63
Publication
First Author: Kayagaki N
Year: 1997
Journal: Proc Natl Acad Sci U S A
Title: Polymorphism of murine Fas ligand that affects the biological activity.
Volume: 94
Issue: 8
Pages: 3914-9
Publication
First Author: Baum PR
Year: 1994
Journal: EMBO J
Title: Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34.
Volume: 13
Issue: 17
Pages: 3992-4001
Publication
First Author: Malipiero U
Year: 1997
Journal: Eur J Immunol
Title: Myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis is chronic/relapsing in perforin knockout mice, but monophasic in Fas- and Fas ligand-deficient lpr and gld mice.
Volume: 27
Issue: 12
Pages: 3151-60
Publication
First Author: Kehren J
Year: 1999
Journal: J Exp Med
Title: Cytotoxicity is mandatory for CD8(+) T cell-mediated contact hypersensitivity.
Volume: 189
Issue: 5
Pages: 779-86
Publication
First Author: Liu Y
Year: 2006
Journal: Blood
Title: Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo.
Volume: 108
Issue: 1
Pages: 123-33
Publication
First Author: Camacho IA
Year: 2005
Journal: J Immunol
Title: Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells.
Volume: 175
Issue: 1
Pages: 90-103
Publication
First Author: Brochard V
Year: 2009
Journal: J Clin Invest
Title: Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.
Volume: 119
Issue: 1
Pages: 182-92
Publication
First Author: Rutigliano JA
Year: 2004
Journal: J Immunol
Title: Prolonged production of TNF-alpha exacerbates illness during respiratory syncytial virus infection.
Volume: 173
Issue: 5
Pages: 3408-17
Publication
First Author: Torrero MN
Year: 2006
Journal: Cancer Res
Title: Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression.
Volume: 66
Issue: 8
Pages: 4461-7
Publication
First Author: Ishikawa T
Year: 2009
Journal: J Virol
Title: Protective role of Fas-FasL signaling in lethal infection with herpes simplex virus type 2 in mice.
Volume: 83
Issue: 22
Pages: 11777-83
Publication
First Author: Chakour R
Year: 2009
Journal: J Leukoc Biol
Title: A new function of the Fas-FasL pathway in macrophage activation.
Volume: 86
Issue: 1
Pages: 81-90
Publication
First Author: Xu X
Year: 2012
Journal: J Immunol
Title: Splenic stroma-educated regulatory dendritic cells induce apoptosis of activated CD4 T cells via Fas ligand-enhanced IFN-γ and nitric oxide.
Volume: 188
Issue: 3
Pages: 1168-77
Publication
First Author: Cone RE
Year: 2007
Journal: Immunology
Title: The suppression of delayed-type hypersensitivity by CD8+ regulatory T cells requires interferon-gamma.
Volume: 120
Issue: 1
Pages: 112-9
Publication
First Author: Zhang Y
Year: 2008
Journal: J Immunol
Title: Th17 cells undergo Fas-mediated activation-induced cell death independent of IFN-gamma.
Volume: 181
Issue: 1
Pages: 190-6
Publication
First Author: Maeda Y
Year: 2005
Journal: Blood
Title: Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease.
Volume: 105
Issue: 5
Pages: 2023-7
Publication
First Author: Hashimoto W
Year: 1999
Journal: J Immunol
Title: Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively.
Volume: 163
Issue: 2
Pages: 583-9
Publication
First Author: He KM
Year: 2007
Journal: Eur J Immunol
Title: Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
Volume: 37
Issue: 12
Pages: 3455-66
Publication
First Author: Fullerton AM
Year: 2013
Journal: Toxicol Appl Pharmacol
Title: 2,3,7,8-TCDD enhances the sensitivity of mice to concanavalin A immune-mediated liver injury.
Volume: 266
Issue: 2
Pages: 317-27
Publication
First Author: Niederkorn JY
Year: 2006
Journal: Am J Transplant
Title: Differential roles of CD8+ and CD8- T lymphocytes in corneal allograft rejection in 'high-risk' hosts.
Volume: 6
Issue: 4
Pages: 705-13
Publication
First Author: Kish DD
Year: 2012
Journal: J Immunol
Title: Neutrophil expression of Fas ligand and perforin directs effector CD8 T cell infiltration into antigen-challenged skin.
Volume: 189
Issue: 5
Pages: 2191-202